Cambridge, UK - 12 January 2022 – Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator empowering life science researchers with high-quality biological reagents and tools critical to research, drug discovery and diagnostics, today received the Employees’ Choice Award 2022 recognizing Abcam in Glassdoor’s Best Places to Work in the UK. Abcam is the first biotech company to be ranked in the top five for two years in a row (1).
As the worldwide leader on insights about jobs and companies, Glassdoor celebrates, each year, outstanding employers throughout the world. Solely based on employees…
12th January 2022 (Rotterdam/Cambridge) – F.INSTITUTE, a Dutch full-service finance company for Life Sciences, Clean and Deep Tech companies, has expanded its portfolio with the launch of three new products: the Incubator, Seed and Series packages. The company has also expanded its CFO Services to include Partnering and M&A Services, and Fundraising Services. These products emphasize F.INSTITUTE’s ambition to become the European one-stop market leader for financial services for start-ups and scale-ups. F.INSTITUTE now offers specific financial packages for a fixed monthly fee to a…
After 15 years in Biotech Tom Froggatt set up Singular Talent to help Biotech companies engage, attract and secure the talent they need and to make the hiring experience better from both sides of the table. He revealed how the values that are the bedrock of the company and .... much more:
Why I started Singular Talent
When I started in recruitment in 2006, the biggest problem we faced was finding and contacting the right people. LinkedIn didn’t exist, and Google was nowhere near the platform it’s now become, so we spent all of our time (and money) on solving this problem – building databases…
Fremont, CA, US and Cambridge, UK – 04 January 2022 – Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences research tools, today announced a strategic partnership to further understanding of the human proteome.
The field of proteomic analysis is in the spotlight. Its advance not only enhances the understanding of fundamental biology, but also sheds light on the status of human health and disease. A deeper…
MAINZ, Germany and CAMBRIDGE, UK, January 10, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Crescendo Biologics Ltd (“Crescendo”), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announced that they have entered a multi-target discovery collaboration to develop novel immunotherapies for the treatment of patients with cancer and other diseases. The initial term of the discovery collaboration is three years.Crescendo will contribute its unique, proprietary, transgenic platform to deliver fully human heavy-chain antibody domains (…
AMSBIO has announced new additions to its portfolio of tools for COVID-19 research - two monoclonal antibodies that recognize the Spike RBD (B.1.1.529, Omicron Variant) protein and neutralizes its interaction with ACE2. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Research has shown that ACE2 mediates COVID-19 infection through direct binding of the SARS-CoV-2 Spike protein. AMSBIO’s new Spike neutralizing monoclonal antibodies (clone G10xA5 and G10xA1) recognize the SARS-CoV-2 Spike RBD (B.1.1.…
• UK CFOs focused on business expansion in 2022
• Record* number of CFOs say increasing capital investment is a strong priority for their business in the year ahead
• Overwhelming majority of CFOs expect greater investment in digital technology and workforce skills over the next three years
• Despite rising inflation and the emergence of the Omicron variant, CFO risk appetite has nudged higher
• CFOs expect productivity to grow faster in the next three years, than in the years before the pandemic
Finance leaders are focused on growth, with a record 37% rating an increase in capital…
Cambridge, UK and Durham, NC, USA, 05 January 2022: PhoreMost Limited, a UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Polaris Quantum Biotech (POLARISqb), a NC-based quantum computing drug design company, today announced a collaboration to study oncology targets currently considered undruggable.
Under the terms of the agreement, the POLARISqb Tachyon™ quantum computing platform will be used to scan billions of molecules from a large chemical space, to find novel molecular drugs, based on the information obtained from PhoreMost’s…
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced that Ares Trading S.A., an affiliate of Merck KGaA, Darmstadt, Germany has exercised a fourth licensing option to develop another bispecific program under the ongoing immuno-oncology collaboration. Under the terms of the agreement, Merck KGaA, Darmstadt, Germany will be responsible for all future…